Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Antioxid Redox Signal ; 18(7): 795-9, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23043315

RESUMEN

The global protein thiol pool has been reported to play a major role in the defense against oxidative stress as a redox buffer similar to glutathione. The present study uses a novel method to visualize cellular changes of the global protein thiol pool in response to induced oxidative stress. Unexpectedly, the results showed an uneven distribution of protein thiols in resting cells with no apparent change in their level or distribution in response to diamide as has been reported previously. Further analysis revealed that thiol pool oxidation is artificially high due to insufficient activity of the widely used sample quencher trichloroacetic acid (TCA). This suggests that previously published articles based on TCA as a quencher should be interpreted with caution as TCA could have caused similar artifacts. Overall, the results presented here question the major role for the global thiol pool in the defense against oxidative stress. Instead our hypothesis is that the fraction of proteins involved in response to oxidative stress is much smaller than previously anticipated in support of a fine-tuned cell signaling by redox regulation.


Asunto(s)
Actinas/metabolismo , Ácido Tricloroacético/metabolismo , Actinas/química , Artefactos , Línea Celular Tumoral , Diamida/farmacología , Células HeLa , Humanos , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Compuestos de Sulfhidrilo/metabolismo , Compuestos de Sulfhidrilo/farmacología
2.
Biochem Biophys Res Commun ; 430(1): 90-4, 2013 Jan 04.
Artículo en Inglés | MEDLINE | ID: mdl-23154180

RESUMEN

Thioredoxin reductase 1 (TrxR1) is a selenocysteine-containing redox-active enzyme that is thought to be important during carcinogenesis. We have recently shown that treatment with statins, HMGCoA reductase inhibitors, reduces the levels of TrxR1 in liver of both rat and human. The reduced TrxR1 levels were correlated with inhibited hepatocarcinogenesis in a rat model. The aim of the present study was to investigate if statins affect the activity of the human TXNRD1 core promoter, which guides expression of TrxR1, and if the effects by statins on TrxR1 expression in liver could be reproduced in a cellular model system. We found that simvastatin and fluvastatin decreased cellular TrxR activity in cultured human liver-derived HepG2 cells with approximately 40% (p<0.05). Simvastatin, but not fluvastatin or atorvastatin, also reduced the TXNRD1 promoter activity in HepG2 cells by 20% (p<0.01). In line with this result, TrxR1 mRNA levels decreased with about 25% in non-transfected HepG2 cells upon treatment with simvastatin (p<0.01). Concomitant treatment with mevalonate could not reverse these effects of simvastatin, indicating that other mechanisms than HMGCoA reductase inhibition was involved. Also, simvastatin did not inhibit sulforaphane-derived stimulation of the TXNRD1 core promoter activity, suggesting that the inhibition by simvastatin was specific for basal and not Nrf2-activated TrxR1 expression. In contrast to simvastatin, the two other statins tested, atorvastatin or fluvastatin, did not influence the TrxR1 mRNA levels. Thus, our results reveal a simvastatin-specific reduction of cellular TrxR1 levels that at least in part involves direct inhibitory effects on the basal activity of the core promoter guiding TrxR1 expression.


Asunto(s)
Hepatocitos/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Regiones Promotoras Genéticas/efectos de los fármacos , Simvastatina/farmacología , Tiorredoxina Reductasa 1/antagonistas & inhibidores , Tiorredoxina Reductasa 1/metabolismo , Animales , Ácidos Grasos Monoinsaturados/farmacología , Fluvastatina , Células Hep G2 , Hepatocitos/metabolismo , Humanos , Indoles/farmacología , ARN Mensajero/antagonistas & inhibidores , Ratas , Tiorredoxina Reductasa 1/genética
3.
Free Radic Biol Med ; 50(11): 1620-9, 2011 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-21397686

RESUMEN

The interactions of selenite and tellurite with cytosolic and mitochondrial thioredoxin reductases (TrxR1 and TrxR2) and glutathione reductases (GR) from yeast and mammalian sources were explored. Both TrxR1 and TrxR2 act as selenite and tellurite reductases. Kinetic treatment shows that selenite has a greater affinity than tellurite with both TrxR1 and TrxR2. Considering both k(cat) and K(m), selenite shows a better catalytic efficiency than tellurite with TrxR1, whereas with TrxR2, the catalytic efficiency is similar for both chalcogens. Tellurite is a good substrate for GR, whereas selenite is almost completely ineffective. Selenite or tellurite determine a large mitochondrial permeability transition associated with thiol group oxidation. However, with increasing concentrations of both chalcogens, only about 25% of total thiols are oxidized. In isolated mitochondria, selenite or tellurite per se does not stimulate H2O2 production, which, however, is increased by the presence of auranofin. They also determine a large oxidation of mitochondrial pyridine nucleotides. In ovarian cancer cells both chalcogens decrease the mitochondrial membrane potential. These results indicate that selenite and tellurite, interacting with the thiol-dependent enzymes, alter the balance connecting pyridine nucleotides and thiol redox state, consequently leading to mitochondrial and cellular alterations essentially referable to a disulfide stress.


Asunto(s)
Glutatión Reductasa/metabolismo , Mitocondrias Hepáticas/metabolismo , Neoplasias Ováricas/metabolismo , Selenito de Sodio/farmacología , Telurio/farmacología , Reductasa de Tiorredoxina-Disulfuro/metabolismo , Animales , Auranofina/farmacología , Línea Celular Tumoral , Permeabilidad de la Membrana Celular/efectos de los fármacos , Femenino , Glutatión Reductasa/química , Humanos , Cinética , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/patología , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/patología , Oxidación-Reducción/efectos de los fármacos , Piridinas/metabolismo , Ratas , Selenito de Sodio/química , Especificidad por Sustrato , Compuestos de Sulfhidrilo/metabolismo , Telurio/química , Reductasa de Tiorredoxina-Disulfuro/química , Levaduras
4.
Antioxid Redox Signal ; 12(7): 867-80, 2010 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-19769465

RESUMEN

Selenium is an essential element that is specifically incorporated as selenocystein into selenoproteins. It is a potent modulator of eukaryotic cell growth with strictly concentration-dependant effects. Lower concentrations are necessary for cell survival and growth, whereas higher concentrations inhibit growth and induce cell death. It is well established that selenium has cancer preventive effects, and several studies also have shown that it has strong anticancer effects with a selective cytotoxicity on malignant drug-resistant cells while only exerting marginal effects on normal and benign cells. This cancer-specific cytotoxicity is likely explained by high affinity selenium uptake dependent on proteins connected to multidrug resistance. One of the most studied selenoproteins in cancer is thioredoxin reductase (TrxR) that has important functions in neoplastic growth and is an important component of the resistant phenotype. Several reports have shown that TrxR is induced in tumor cells and pre-neoplastic cells, and several commonly used drugs interact with the protein. In this review, we summarize the current knowledge of selenium as a potent preventive and tumor selective anticancer drug, and we also discuss the potential of using the expression and modulation of the selenoprotein TrxR in the diagnostics and treatment of cancer.


Asunto(s)
Neoplasias/diagnóstico , Neoplasias/prevención & control , Neoplasias/terapia , Selenio/metabolismo , Reductasa de Tiorredoxina-Disulfuro/metabolismo , Empalme Alternativo , Antioxidantes/metabolismo , Biomarcadores/metabolismo , Ensayos Clínicos como Asunto , Suplementos Dietéticos , Diseño de Fármacos , Exones , Humanos , Neoplasias/metabolismo , Oxidantes/metabolismo , Oxidación-Reducción , Selenio/uso terapéutico , Reductasa de Tiorredoxina-Disulfuro/genética
5.
Histopathology ; 55(3): 313-20, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19723146

RESUMEN

AIMS: Lung cancer is one of the most common causes of cancer lethality worldwide. Despite recent progress, long-term survival remains poor. The aim of this study was to explore the expression pattern of the thioredoxin superfamily of proteins as potential new diagnostic and/or predictive markers. METHODS AND RESULTS: The expression of thioredoxin 1 (Trx1), thioredoxin reductase 1 (TrxR1), the isoforms TrxR1-v.2,3,5, glutaredoxin 1 (Grx1) and glutaredoxin 2 (Grx2) was examined by immunohistochemistry on paraffin-embedded sections from 42 cases of non-small cell lung cancer patients. Additional cases of lung cancer from tissue microarray were examined and the immunoreactivity was compared. All proteins except TrxR1 showed a significant correlation with the degree of differentiation in adenocarcinoma. Trx1 and TrxR1-v.2,3,5 also showed a significant correlation with differentiation in squamous carcinoma. Furthermore, Grx1 and Grx2 showed a clear inverse correlation with proliferation. The proliferation rate was further analysed in vitro in stably transfected Grx2 overproducing cells, showing that the proliferative effect of Grx2 is strictly dependent on subcellular localization. CONCLUSIONS: The thioredoxin family of proteins is important for growth and differentiation of lung cancer cells. The correlation with differentiation and proliferation of these enzymes makes them promising predictive/diagnostic markers.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Transformación Celular Neoplásica , Neoplasias Pulmonares/metabolismo , Tiorredoxina Reductasa 1/metabolismo , Tiorredoxinas/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Adulto , Anciano , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Grandes/metabolismo , Carcinoma de Células Grandes/patología , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patología , Proliferación Celular , Femenino , Glutarredoxinas/metabolismo , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Análisis de Matrices Tisulares
6.
J Exp Clin Cancer Res ; 28: 92, 2009 Jun 29.
Artículo en Inglés | MEDLINE | ID: mdl-19563663

RESUMEN

BACKGROUND: Selenite is a promising anticancer agent which has been shown to induce apoptosis in malignant mesothelioma cells in a phenotype-dependent manner, where cells of the chemoresistant sarcomatoid phenotype are more sensitive. METHODS: In this paper, we investigate the apoptosis signalling mechanisms in sarcomatoid and epithelioid mesothelioma cells after selenite treatment. Apoptosis was measured with the Annexin-PI assay. The mitochondrial membrane potential, the expression of Bax, Bcl-XL, and the activation of caspase-3 were assayed with flow cytometry and a cytokeratin 18 cleavage assay. Signalling through JNK, p38, p53, and cathepsins B, D, and E was investigated with chemical inhibitors. Furthermore, the expression, nuclear translocation and DNA-binding activity of p53 was investigated using ICC, EMSA and the monitoring of p21 expression as a downstream event. Levels of thioredoxin (Trx) were measured by ELISA. RESULTS: In both cell lines, 10 microM selenite caused apoptosis and a marked loss of mitochondrial membrane potential. Bax was up-regulated only in the sarcomatoid cell line, while the epithelioid cell line down-regulated Bcl-XL and showed greater caspase-3 activation. Nuclear translocation of p53 was seen in both cell lines, but very little p21 expression was induced. Chemical inhibition of p53 did not protect the cells from apoptosis. p53 lost its DNA binding ability after selenite treatment and was enriched in an inactive form. Levels of thioredoxin decreased after selenite treatment. Chemical inhibition of MAP kinases and cathepsins showed that p38 and cathepsin B had some mediatory effect while JNK had an anti-apoptotic role. CONCLUSION: We delineate pathways of apoptosis signalling in response to selenite, showing differences between epithelioid and sarcomatoid mesothelioma cells. These differences may partly explain why sarcomatoid cells are more sensitive to selenite.


Asunto(s)
Apoptosis/efectos de los fármacos , Mesotelioma/tratamiento farmacológico , Mesotelioma/patología , Transducción de Señal/efectos de los fármacos , Selenito de Sodio/farmacología , Caspasa 3/metabolismo , Proliferación Celular , Citometría de Flujo , Humanos , Técnicas para Inmunoenzimas , Luciferasas/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Fenotipo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Tiorredoxinas , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/metabolismo , Proteína X Asociada a bcl-2/metabolismo
7.
Free Radic Biol Med ; 47(6): 710-21, 2009 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-19486940

RESUMEN

Selenium is an essential trace element incorporated as selenocysteine in 25 human selenoproteins. Among them are thioredoxin reductases (TrxR) and glutathione peroxidases, all central proteins in the regulation of the cellular thiol redox state. In this paper the effects of selenite and tellurite treatment in human cancer cells are reported and compared. Our results show that both selenite and tellurite, at relatively low concentrations, are able to increase the expression of mitochondrial and cytosolic TrxR in cisplatin-sensitive (2008) and -resistant (C13*) phenotypes. We further investigated the cellular effects induced by selenite or tellurite in combination with the specific TrxR inhibitor auranofin. Selenite pretreatment induced a dramatic increase in auranofin cytotoxicity in both resistant and sensitive cells. Investigation of TrxR activity and expression levels as well as the cellular redox state demonstrated the involvement of TrxR inhibition and redox changes in selenite and auranofin combined action.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Ováricas/tratamiento farmacológico , Selenito de Sodio/farmacología , Telurio/farmacología , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Adenocarcinoma/secundario , Auranofina/farmacología , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Cisplatino/uso terapéutico , Resistencia a Antineoplásicos , Inhibidores Enzimáticos/farmacología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Neoplasias Ováricas/genética , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/secundario , Selenito de Sodio/uso terapéutico , Telurio/uso terapéutico , Reductasa de Tiorredoxina-Disulfuro/genética , Reductasa de Tiorredoxina-Disulfuro/metabolismo
8.
Proc Natl Acad Sci U S A ; 106(27): 11400-5, 2009 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-19549867

RESUMEN

The selenium salt selenite (SeO(3)(2-)) is cytotoxic in low to moderate concentrations, with a remarkable specificity for cancer cells resistant to conventional chemotherapy. Our data show that selenium uptake and accumulation, rather than intracellular events, are crucial to the specific selenite cytotoxicity observed in resistant cancer cells. We show that selenium uptake depends on extracellular reduction, and that the extracellular environment is a key factor specific to selenite cytotoxicity. The extracellular reduction is mediated by cysteine, and the efficacy is determined by the uptake of cystine by the x(c)(-) antiporter and secretion of cysteine by multidrug resistance proteins, both of which are frequently overexpressed by resistant cancer cells. This mechanism provides molecular evidence for the existence of an inverse relationship between resistance to conventional chemotherapy and sensitivity to selenite cytotoxicity, and highlights the great therapeutic potential in treating multidrug-resistant cancer.


Asunto(s)
Sistema de Transporte de Aminoácidos y+/metabolismo , Cistina/metabolismo , Espacio Extracelular/metabolismo , Neoplasias Pulmonares/metabolismo , Selenio/metabolismo , Selenito de Sodio/toxicidad , Compuestos de Sulfhidrilo/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antiportadores/metabolismo , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Cistina/análogos & derivados , Cistina/farmacología , Resistencia a Antineoplásicos/efectos de los fármacos , Espacio Extracelular/efectos de los fármacos , Glutatión/análogos & derivados , Glutatión/farmacología , Humanos , Modelos Biológicos , Compuestos de Organoselenio/farmacología , Oxidación-Reducción/efectos de los fármacos
9.
Cancer Lett ; 282(1): 116-23, 2009 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-19345479

RESUMEN

Selenite is a potent inhibitor of malignant cell growth. Although the cytotoxic effects have been extensively investigated in vitro, there are only a limited number of studies using primary tumor cells with concomitant comparison to conventional drugs. An ex vivo model with primary cells from 39 consecutive patients with acute myeloid leukemia (AML) were exposed to a panel of conventional cytotoxic drugs, and the effects on viability were compared to those of clinically achievable concentrations of selenite. Selenite at 5 microM caused the lowest mean survival of primary tumor cells in the panel of all tested drugs (28.95% CI 18.60-39.30%). The cells showed a significant (p<0.05) correlation in the resistance to all tested conventional AML drugs whereas selenite did not, indicating sensitivity to selenite also in multi drug resistant cells. Exposure to selenite also resulted in an increased mRNA expression of the antioxidant proteins TrxR1 and Grx, while staining for TrxR1 showed decreased protein levels. The results strongly suggest a great potential for selenite in the treatment of multi drug resistant AML.


Asunto(s)
Citotoxinas/farmacología , Leucemia Mieloide Aguda/patología , Selenito de Sodio/farmacología , Adenosina Trifosfato/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Supervivencia Celular/efectos de los fármacos , Femenino , Humanos , Inmunohistoquímica , Leucemia Mieloide Aguda/clasificación , Leucemia Mieloide Aguda/tratamiento farmacológico , Masculino , Persona de Mediana Edad
10.
FEBS J ; 276(2): 532-40, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19077163

RESUMEN

Pycnogenol, which is extracted from the bark of French maritime pine, has been shown to have antioxidant and free radical scavenging activities. Thioredoxin reductase (TrxR), glutathione peroxidase (GPx) and glutathione reductase (GR) are three central redox enzymes that are active in endogenous defence against oxidative stress in the cell. Treatment of cells with Pycnogenol decreased the activity of both TrxR and GPx in cells by more than 50%, but GR was not affected. As previously reported, both enzymes were induced after treatment with hydrogen peroxide and selenite. The presence of Pycnogenol efficiently decreased selenite-mediated reactive oxygen species (ROS) production. Addition of Pycnogenol after selenite treatment reduced the mRNA expression and activity of TrxR to basal levels. In contrast, the GPx activity was completely unaffected. The discrepancy between TrxR and GPx regulation may indicate that transcription of TrxR is induced primarily by oxidative stress. As TrxR is induced in various pathological conditions, including tumours and inflammatory conditions, decreased activity mediated by a non-toxic agent such as Pycnogenol may be of great value.


Asunto(s)
Antioxidantes/farmacología , Flavonoides/farmacología , Neoplasias Pulmonares/metabolismo , Supervivencia Celular/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/genética , Glutarredoxinas/metabolismo , Humanos , Concentración 50 Inhibidora , Neoplasias Pulmonares/patología , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales , ARN Mensajero/genética , Especies Reactivas de Oxígeno/metabolismo , Selenito de Sodio/farmacología , Reductasa de Tiorredoxina-Disulfuro/genética , Reductasa de Tiorredoxina-Disulfuro/metabolismo , Factores de Tiempo
11.
Biochem Pharmacol ; 75(11): 2092-9, 2008 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-18405881

RESUMEN

Selenium at subtoxic doses has been shown to have tumor specific cytotoxic effects. In this work, viability measurements in different lung cancer cell lines showed that selenite was more effective compared to three different conventional cytotoxic drugs. In addition, the cell line most sensitive to selenite toxicity comprised the highest level of thioredoxin reductase 1 (TrxR1). The human selenoenzyme TrxR1 is a central enzyme for cell growth, differentiation, and the protection against oxidative stress. TrxR1, which in several studies has been shown to be up-regulated in various tumor cells, is also a target for many anticancer drugs. In this study, inhibition of TrxR resulted in enhanced selenite cytotoxicity, clearly connecting the thioredoxin system to the toxic effects mediated by selenite. The complex regulation of TrxR1, involving the expression of many different transcript forms of mRNA, was investigated by real-time qPCR in lung cancer cell lines following treatment with toxic doses (2.5-10 microM) of sodium selenite. Selenium treatment resulted in increased expression of almost all TrxR1 mRNA variants with increasing concentrations of selenite. On the contrary, the TrxR protein level and activity, increased at low to moderate doses followed by a decrease at higher doses, indicating impairment of protein synthesis by selenite.


Asunto(s)
Antineoplásicos/toxicidad , Neoplasias Pulmonares/tratamiento farmacológico , Selenito de Sodio/toxicidad , Tiorredoxinas/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Neoplasias Pulmonares/patología , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Tiorredoxina Reductasa 1/metabolismo
12.
Differentiation ; 75(2): 123-32, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17316382

RESUMEN

The human selenoenzyme thioredoxin reductase 1 (TrxR1) is a very important enzyme for cell growth, differentiation, and the defense against oxidative stress. Several studies have shown that TrxR1 is up-regulated in tumor cells. The regulation of TrxR1 is very complex and involves the expression of different transcript forms of mRNA. We have, by quantitative polymerase chain reaction, investigated the total expression of TrxR1 mRNA and quantified the expression of alternative mRNA forms (alpha1/2, alpha6, alpha7/8, alpha10/11, alpha13, gamma2-4, and beta1) in six different human malignant mesothelioma cell lines of epithelioid, sarcomatoid, or mixed phenotype. The most abundant alpha-form was surprisingly alpha1/2 and not the expected alpha7/8. Selenium treatment resulted in increased expression of all alpha-variants, except the alpha10/11, where the levels were unaffected. The expression of protein isoforms was studied and the less abundant forms TrxR1v.2, TrxR1v.3, and TrxR1v.5 were detected in cell lysates and in human tumor tissue, using specific peptide antibodies. Furthermore, TrxR1v.3 and TrxR1v.5, previously not identified in human cells, were detected by mass spectrometry. Our data show differential expression of TrxR1 mRNA forms in malignant mesothelioma of different phenotype, and investigation of alternative transcript variants of TrxR1 could be a valuable tool in the diagnostics and characterization of tumors.


Asunto(s)
Empalme Alternativo , Regulación Enzimológica de la Expresión Génica , Mesotelioma/enzimología , ARN Mensajero/genética , Reductasa de Tiorredoxina-Disulfuro/genética , Células Epitelioides/enzimología , Humanos , Isoenzimas , Espectrometría de Masas , Mesotelioma/clasificación , Mesotelioma/genética , Fragmentos de Péptidos/análisis , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Selenio/farmacología , Reductasa de Tiorredoxina-Disulfuro/metabolismo , Tiorredoxinas , Células Tumorales Cultivadas
13.
Free Radic Biol Med ; 41(6): 874-85, 2006 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-16934670

RESUMEN

Malignant mesothelioma cells differentiate into sarcomatoid or epithelioid phenotypes. The sarcomatoid cell type is more resistant to chemotherapy and gives a worse prognosis. We have investigated whether selenite alone and in combination with doxorubicin induced apoptosis in variously differentiated mesothelioma cells. Selenite in concentrations that could potentially be administered to patients strongly inhibited the growth of the sarcomatoid mesothelioma cells (IC50 = 7.5 microM), whereas epithelioid cells were more sensitive to doxorubicin. Benign mesothelial cells remained largely unaffected. Selenite potentiated doxorubicin treatment. Apoptosis was the dominating mode of cell death. The toxicity of selenite was mediated by oxidative stress. Furthermore the activity of the thioredoxin system was directly dependent on the concentration of selenite. This offers a possible mechanism of action of selenite treatment. Our findings suggest that selenite is a promising new drug for the treatment of malignant mesothelioma.


Asunto(s)
Apoptosis/efectos de los fármacos , Mesotelioma/patología , Estrés Oxidativo/fisiología , Selenito de Sodio/toxicidad , Adenocarcinoma , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Humanos , Estrés Oxidativo/efectos de los fármacos , Compuestos de Sulfhidrilo/metabolismo
14.
Free Radic Biol Med ; 36(5): 641-56, 2004 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-14980707

RESUMEN

Human thioredoxin reductase 1 (TrxR1, the TXNRD1 gene product) is a ubiquitously expressed selenoprotein with many important redox regulatory functions. In this study, we have further characterized the recently identified core promoter region of TXNRD1. One critical Sp1/Sp3 site was found to be important in A549 and HeLa cells, whereas another Sp1/Sp3 site and one Oct1 site bound transcription factors but were, nonetheless, dispensable for transcription. We also experimentally identified several 5'-region TXNRD1 transcript variants using 5'-RACE with cDNA derived from different tissues, and we analyzed all available TXNRD1-derived EST sequences. The results show that the core promoter governs transcription of the clear majority of TXNRD1 transcripts but also that alternative promoters may be activated under rare conditions or in specific cell types. Furthermore, extensive alternative splicing occured in the 5' region of TXNRD1. In total, 21 different transcripts were identified, potentially encoding five isoforms of TrxR1 carrying alternative N-terminal domains. One isoform encompassed a glutaredoxin domain, whereas another encoded a predicted mitochondrial localization signal. These results reveal that the human thioredoxin system is intriguingly complex. Cell-specific transcription of the TXNRD1 gene encoding different isoforms of TrxR1 must be taken into account to fully understand the functions of the human thioredoxin system.


Asunto(s)
Empalme Alternativo/genética , Regiones Promotoras Genéticas/genética , Reductasa de Tiorredoxina-Disulfuro/genética , Transcripción Genética/genética , Secuencia de Aminoácidos , Clonación Molecular , Ensayo de Cambio de Movilidad Electroforética , Genes Reporteros/genética , Células HeLa , Humanos , Datos de Secuencia Molecular , Isoformas de Proteínas/genética , Estructura Terciaria de Proteína/genética , Tiorredoxina Reductasa 1 , Factores de Transcripción/genética , Células Tumorales Cultivadas
15.
Antioxid Redox Signal ; 6(1): 41-52, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14980055

RESUMEN

Reactive oxygen species (ROS) are generated as toxic by-products of aerobic metabolism, but are also essential biomolecules in cell signaling. The thioredoxin (Trx) system is a major enzymatic system modulating ROS levels and is important for redox regulation of cellular function. It consists of Trx and thioredoxin reductase (TrxR), which reduces Trx using NADPH. Most, if not all, of the functions of Trx depend on the activity of TrxR. Mammalian TrxR enzymes are selenoproteins with broad substrate specificities, and alteration of cytosolic TrxR1 expression and activity is likely to be an important determinant for the control of cellular redox regulation. TrxR1 activity in cells seems to be modulated by an intricate interplay, involving a housekeeping type promoter in combination with alternative splice variants and transcriptional start sites, posttranscriptional regulation through AU-rich elements, inactivation by electrophilic agents and by itself modulating the effects of several key signaling molecules. TrxR1 activity is also intimately linked with several aspects of selenium metabolism, and hence selenoprotein function in general. Here, we summarize the current knowledge of these different levels of TrxR1 regulation in diverse cell types and in response to growth and signaling events.


Asunto(s)
Fenotipo , Proteínas/metabolismo , Transducción de Señal , Reductasa de Tiorredoxina-Disulfuro/genética , Reductasa de Tiorredoxina-Disulfuro/metabolismo , Animales , División Celular/fisiología , Regulación Enzimológica de la Expresión Génica , Humanos , Oxidación-Reducción , Especies Reactivas de Oxígeno/metabolismo , Selenoproteínas , Tiorredoxina Reductasa 1 , Tiorredoxinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA